Hepatic-arterial chemotherapy.
The liver is a common site of metastases from cancers from most sites, but particularly from the gastrointestinal tract, since the portal vein drains into the liver. About half of all patients with colorectal cancer develop liver metastases. The response of liver metastases to systemic combination chemotherapy has improved, but the 2-year survival is only 25-30%. Hepatic-arterial infusion of chemotherapy produces higher response rates, with a 2-year survival of 50-60%. In patients who can undergo liver resection followed by hepatic-arterial infusion, the 2-year survival is 85%. This review summarises the anatomical basis, pharmacokinetic background, and cost-effectiveness of this procedure. We discuss the phase II and phase III studies of hepatic-arterial infusion therapy, with a focus on liver metastases from colorectal cancer.
Kemeny
N
N
Memorial Sloan-Kettering Cancer Center, Gastrointestinal Oncology Service, New York, NY 10021, USA. Kemenyn@mskcc.org
Fata
F
F
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002408:Catheters, Indwelling; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology; D003362:Cost-Benefit Analysis; D006499:Hepatic Artery; D006801:Humans; D015918:Infusion Pumps, Implantable; D007261:Infusions, Intra-Arterial / Q000009:adverse effects / Q000191:economics; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary
D000970:Antineoplastic Agents